Back to market on close. I'm Marley Caden here in Chicago alongside Sam Vodis at the New York Stock Exchange. Some final thoughts on today's session.Of course, we got the CPI report. The consumer price index rose 2.7% in November. According to the delayed data that we got from the BLS this morning that was less than the 3.1% expected, reigniting some hopes that the Fed may be able to ease more than expected.Core CPI was also cooler than anticipated, increasing 2.6% over 12 months. It was expected to have ri ...

Clinical Trial & Drug Performance - Novo's Alzheimer's drug trial (using weight loss drug MGovi) failed to meet its primary goal, showing no statistically significant slowing of Alzheimer's progression [1][2][3] - The trial results suggest that GLP-1s, while a new mechanism, may require combination with other drugs to be effective in treating Alzheimer's [8] - Biogen and Lily are considered the main players in the Alzheimer's space, with many other companies in earlier phases of development [8][9] Competitive Landscape & Market Share - Lily is perceived as consistently delivering best-in-class GLP-1 growth in obesity and diabetes, with a next product in orphagon [4] - Lily's Mjaro and Zetbound are growing significantly, taking market share from Novo [6] - Lily's market share has increased from 50% to approximately 75%, while Novo's has decreased to around 25% [11] Financial Analysis & Future Outlook - Analyst has a street-high target of $1500 for Lily, driven by the company's core business in the US [5] - Lily is expected to benefit significantly from locking in Medicare and Medicaid payer segments in the next 2-3 years, offsetting lower prices with higher volumes [10] - The Total Addressable Market (TAM) for obesity and diabetes drugs is expected to grow dramatically with expanded access to Medicare and Medicaid [12][14] - Analyst suggests that Lily is a better investment than Novo due to its pipeline, growth in the US and internationally, and overall investment in the space [13]

Company Overview - Novo's shares have fallen to a four-year low following the failure of its Alzheimer's drug trial, which did not meet its primary goal of slowing disease progression [1] - The trial results for Novo's weight loss drug MGovi were disappointing, leading to a significant drop in investor confidence [2] Market Comparison - There is a notable disparity in share prices between Novo and its competitor Lilly, with Lilly continuing to perform well in the GLP-1 market for obesity and diabetes [3][4] - Lilly's products, such as Mjaro and Zetbound, are experiencing significant growth and taking market share from Novo [6][11] Future Outlook - Despite the setback for Novo, there is still potential for GLP-1 drugs to be effective in treating Alzheimer's when combined with other therapies, indicating ongoing research opportunities in this area [8][9] - The total addressable market (TAM) for obesity drugs is expected to grow significantly, particularly with expanded access to Medicare and Medicaid [12] Investment Perspective - Analysts suggest that investing in Lilly may be more favorable than Novo, given Lilly's strong pipeline and growth trajectory in the obesity and diabetes sectors [13]